HPBCD in vaccine development

Posted by

Pharmaceutical Technology has published an evaluation from experts on vaccine development.

According to recent market research, the vaccines market is expected to grow at a compound annual rate of 14.7% for the forecast period of 2020–2026, the growth of which has been accelerated by the recent COVID-19 pandemic.

The main challenges include antigenic shift (Antigenic shift of organisms yields frequent new variants, which develop very quickly, subsequently requiring surveillance, identification, and recomposition of the modified vaccine antigen or strain, often with a seasonal cyclicality), scalability, robustness, efficiency, cost, and also effficacy and stability.

The author placed a special emphasis on HPBCD: the critical role of functional excipients, specifically cyclodextrins, is gaining interest for those in vaccine development seeking to overcome formulation challenges and produce a safe and efficacious vaccine quickly. “Cyclodextrins are a family of oligosaccharides produced from starch using enzymatic conversion,” she states. “2-hydroxypropyl-beta-cyclodextrin (HPβCD), in particular, is reaching into therapeutic biologic processes, final formulations, and delivery of vaccines, and is being used in some promising new areas where work is still at a very early stage.”

Felicity Thomas (2021) Overcoming Vaccine Development Challenges. Pharmaceutical Technology 45( 5) 24–28. https://www.pharmtech.com/view/overcoming-vaccine-development-challenges


Leave a Reply

This site uses Akismet to reduce spam. Learn how your comment data is processed.